- Record: found
- Abstract: found
- Article: not found
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Hagop Kantarjian
1 ,
Jean-Pierre J Issa ,
Craig S Rosenfeld ,
John M Bennett ,
Maher Albitar ,
John DiPersio ,
Virginia Klimek ,
James Slack ,
Carlos de Castro ,
Farhad Ravandi ,
Richard Helmer ,
Lanlan Shen ,
Stephen D Nimer ,
Richard Leavitt ,
Azra Raza ,
Hussain Saba
Apr 15 2006
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy. Decitabine indirectly depletes methylcytosine and causes hypomethylation of target gene promoters.